HomeCompareSYN vs MO

SYN vs MO: Dividend Comparison 2026

SYN yields 196.08% · MO yields 6.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MO wins by $1.2K in total portfolio value· pulled ahead in Year 10
10 years
SYN
SYN
● Live price
196.08%
Share price
$1.02
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$76.5K
Annual income
$74.42
Full SYN calculator →
MO
Altria Group Inc.
● Live price
6.27%
Share price
$67.02
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$77.7K
Annual income
$28,968.54
Full MO calculator →

Portfolio growth — SYN vs MO

📍 MO pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSYNMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SYN + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SYN pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SYN
Annual income on $10K today (after 15% tax)
$16,666.67/yr
After 10yr DRIP, annual income (after tax)
$63.26/yr
MO
Annual income on $10K today (after 15% tax)
$532.68/yr
After 10yr DRIP, annual income (after tax)
$24,623.26/yr
At 15% tax rate, MO beats the other by $24,560.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SYN + MO for your $10,000?

SYN: 50%MO: 50%
100% MO50/50100% SYN
Portfolio after 10yr
$77.1K
Annual income
$14,521.48/yr
Blended yield
18.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

SYN
Analyst Ratings
5
Buy
2
Hold
Consensus: Buy
Altman Z
-14.5
Piotroski
2/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-8.6% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SYN buys
0
MO buys
11
PoliticianChamberTickerTypeAmountDate
Ro Khanna🏢 House$MO▲ Buy$1,000 - $15,0002025-08-04
Sheri Biggs🏢 House$MO▼ Sell$1,001 - $15,0002025-03-19
Pete Sessions🏢 House$MO▼ Sell$1,001 - $15,0002024-09-10
Ro Khanna🏢 House$MO▲ Buy$1,001 - $15,0002024-03-20
Ro Khanna🏢 House$MO▲ Buy$1,001 - $15,0002024-02-13
Virginia Foxx🏢 House$MO▼ Sell$1,001 - $15,0002024-01-16
Virginia Foxx🏢 House$MO▲ Buy$1,001 - $15,0002024-01-11
Ro Khanna🏢 House$MO▼ Sell$1,001 - $15,0002024-01-10
Ro Khanna🏢 House$MO▲ Buy$1,001 - $15,0002024-01-10
Virginia Foxx🏢 House$MO▼ Sell$15,001 - $50,0002024-01-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSYNMO
Forward yield196.08%6.27%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%22.6%
Portfolio after 10y$76.5K$77.7K
Annual income after 10y$74.42$28,968.54
Total dividends collected$34.4K$72.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: SYN vs MO ($10,000, DRIP)

YearSYN PortfolioSYN Income/yrMO PortfolioMO Income/yrGap
1$20,504$9,803.92$10,558$768.31+$9.9KSYN
2$31,333$9,393.40$11,352$1,015.87+$20.0KSYN
3$40,234$6,707.62$12,482$1,367.86+$27.8KSYN
4$47,075$4,024.82$14,103$1,883.39+$33.0KSYN
5$52,570$2,200.55$16,472$2,664.91+$36.1KSYN
6$57,399$1,148.35$20,024$3,897.79+$37.4KSYN
7$62,003$585.89$25,537$5,933.74+$36.5KSYN
8$66,638$295.74$34,478$9,476.77+$32.2KSYN
9$71,452$148.53$49,776$16,022.63+$21.7KSYN
10← crossover$76,528$74.42$77,699$28,968.54$1.2KMO

SYN vs MO: Complete Analysis 2026

SYNStock

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.

Full SYN Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this SYN vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SYN vs SCHDSYN vs JEPISYN vs OSYN vs KOSYN vs MAINSYN vs PMSYN vs BTISYN vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.